Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration

Stefano Gazzina, Gesine Respondek, Yaroslau Compta, Kieren S.J. Allinson, Maria G. Spillantini, Laura Molina-Porcel, Mar Guasp-Verdaguer, Shirin Moftakhar, Stephen G. Reich, Deborah Hall, Irene Litvan, View ORCID ProfileGünter U. Höglinger, Movement Disorder Society-endorsed PSP Study Group, View ORCID ProfileJames B. Rowe
doi: https://doi.org/10.1101/520510
Stefano Gazzina
1Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
2Department of Clinical Neurosciences, University of Brescia, Brescia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gesine Respondek
3Department of Neurology, Technische Universität München, and German Center for Neurodegenerative Diseases [DZNE), Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaroslau Compta
4Parkinson’s Disease & Movement Disorders Unit, Hospital Clínic, IDIBAPS, CIBERNED, University of Barcelona, Barcelona, Catalonia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kieren S.J. Allinson
5Department of Pathology, Addenbrooke’s Hospital, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria G. Spillantini
1Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Molina-Porcel
6Neurological Tissue Bank of the Biobanc-Hospital Clínic-IDIBAPS, Barcelona, Catalonia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mar Guasp-Verdaguer
4Parkinson’s Disease & Movement Disorders Unit, Hospital Clínic, IDIBAPS, CIBERNED, University of Barcelona, Barcelona, Catalonia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shirin Moftakhar
7Parkinson and Other Movement Disorders Center, Department of Neuroscience, University of California, San Diego, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen G. Reich
8Department of Neurology, University of Maryland, Baltimore, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah Hall
9Department of Neurological Sciences, Rush University, Chicago, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Litvan
7Parkinson and Other Movement Disorders Center, Department of Neuroscience, University of California, San Diego, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Günter U. Höglinger
3Department of Neurology, Technische Universität München, and German Center for Neurodegenerative Diseases [DZNE), Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Günter U. Höglinger
James B. Rowe
1Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James B. Rowe
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

ABSTRACT

Background Progressive supranuclear palsy (PSP) is clinically heterogeneous. Clinical diagnostic criteria were revised in 2017, to increase sensitivity and operationalize the diagnosis of PSP Richardson’s syndrome (PSP-RS) and “variant” syndromes (vPSP).

Objectives To determine the (1) sensitivity and specificity of the 1996 NINDS-SPSP and 2017 MDS-PSP criteria; (2) false positive rates in frontotemporal dementia with frontotemporal lobar degeneration (FTLD); and (3) clinical evolution of variant PSP syndromes (vPSP).

Methods Retrospective multicenter review of 108 neuropathologically-confirmed PSP patients and 81 patients with other forms of FTLD: 38 behavioral variant frontotemporal dementia (bvFTD), 14 non-fluent/agrammatic variant primary progressive aphasia (nfvPPA), and 29 corticobasal degeneration (CBD), Sensitivity and specificity of the MDS-PSP criteria were compared to the NINDS-SPSP criteria at baseline. In a subset of cases, the timing and frequency of clinical features were compared across groups over six years.

Results Sensitivity for recognition of probable and possible PSP pathology was higher by MDS-PSP criteria (72.2-100%) than NINDS-SPSP criteria (48.1-61.1%). Specificity was higher by NINDS-SPSP criteria (97.5-100%) than MDS-PSP criteria (53.1-95.1%). False positives by MDS-PSP criteria were few for bvFTD (10.5-18.4%) but common for CBD and nfvPPA (fulfilling “suggestive of’ PSP). Most vPSP cases developed PSP-RS-like features within six years, including falls and supranuclear gaze palsy, distinguishing frontal presentations of PSP from bvFTD, and speech/language presentations of PSP from nfvPPA.

Conclusions The 2017 MDS-PSP criteria successfully identify PSP, including variant phenotypes. This independent validation of the revised clinical diagnostic criteria strengthens the case for novel therapeutic strategies against PSP to include variant presentations.

Footnotes

  • Financial disclosure/Conflict of interest: Nothing to declare

  • Funding sources: James B. Rowe is supported by the Wellcome Trust (103838). The Cambridge Brain bank is supported by the National Institute for Health Research Biomedical Research Centre. Günter Höglinger was funded by the Deutsche Forschungsgemeinschaft (DFG, HO2402/6-2 & Munich Cluster for Systems Neurology SyNergy). Yaroslau Compta was funded by the CERCA Programme of the Generalitat de Laura Molina-Porcel is supported by the “Fundació Marató de TV3” Grant (20141610). Irene Litvan research is supported by the US National Institutes of Health 5P50 AG005131-31, 5T35HL007491,1U01NS086659 and 1U54NS092089-01; Parkinson Study Group, Michael J Fox Foundation, AVID Pharmaceuticals, C2N Diagnostics/Abbvie and Bristol-Myers Squibb/Biogen. She was a member of the Abbvie advisory board, Biotie/Parkinson Study Group Medical Advisory Board, and Toyama Pharmaceuticals consultant. She receives her salary from the University of California San Diego and as Chief Editor of Frontiers in Neurology. Cases contributed were participants in the ENGENE-PSP study funded by US National Institutes of Health 5R01AG024040.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 15, 2019.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration
Stefano Gazzina, Gesine Respondek, Yaroslau Compta, Kieren S.J. Allinson, Maria G. Spillantini, Laura Molina-Porcel, Mar Guasp-Verdaguer, Shirin Moftakhar, Stephen G. Reich, Deborah Hall, Irene Litvan, Günter U. Höglinger, Movement Disorder Society-endorsed PSP Study Group, James B. Rowe
bioRxiv 520510; doi: https://doi.org/10.1101/520510
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration
Stefano Gazzina, Gesine Respondek, Yaroslau Compta, Kieren S.J. Allinson, Maria G. Spillantini, Laura Molina-Porcel, Mar Guasp-Verdaguer, Shirin Moftakhar, Stephen G. Reich, Deborah Hall, Irene Litvan, Günter U. Höglinger, Movement Disorder Society-endorsed PSP Study Group, James B. Rowe
bioRxiv 520510; doi: https://doi.org/10.1101/520510

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neuroscience
Subject Areas
All Articles
  • Animal Behavior and Cognition (4094)
  • Biochemistry (8784)
  • Bioengineering (6490)
  • Bioinformatics (23377)
  • Biophysics (11761)
  • Cancer Biology (9163)
  • Cell Biology (13267)
  • Clinical Trials (138)
  • Developmental Biology (7420)
  • Ecology (11380)
  • Epidemiology (2066)
  • Evolutionary Biology (15109)
  • Genetics (10408)
  • Genomics (14017)
  • Immunology (9133)
  • Microbiology (22085)
  • Molecular Biology (8792)
  • Neuroscience (47417)
  • Paleontology (350)
  • Pathology (1421)
  • Pharmacology and Toxicology (2483)
  • Physiology (3710)
  • Plant Biology (8060)
  • Scientific Communication and Education (1433)
  • Synthetic Biology (2213)
  • Systems Biology (6019)
  • Zoology (1251)